多发性硬化与脓毒症死亡率的相关性:一项基于人群的分析
该研究为基于德州全州数据的回顾性人群队列研究,纳入2010-2017年≥18岁脓毒症住院患者283,025例,其中多发性硬化(MS)1,687例(0.6%)。MS组较无MS组更年轻(≥65岁35.0% vs 56.8%)、少数族裔比例更低(36.2% vs 48.1%)、Deyo合并症指数均值更低(1.6 vs 2.7),两组脓毒性休克(58.7% vs 59.6%)和ICU入住率(46.7% vs 46.0%)相近。校正分析显示MS与短期死亡率降低17%相关(aOR 0.828,95%CI 0.723-0.947);脓毒性休克亚组结果一致(aOR 0.764,95%CI 0.651-0.896);ICU入住患者中MS与死亡率无关(aOR 0.914,95%CI 0.759-1.101)。
要点
- 在283,025例脓毒症住院患者中,合并MS者短期死亡率校正后降低17%(aOR 0.828,95%CI 0.723-0.947)。
- 脓毒性休克亚组中MS仍与短期死亡率降低相关(aOR 0.764,95%CI 0.651-0.896)。
- 入住ICU的脓毒症患者中,MS与死亡率无关(aOR 0.914,95%CI 0.759-1.101)。
- MS组患者更年轻(≥65岁35.0% vs 56.8%)、Deyo合并症指数更低(1.6 vs 2.7),但两组脓毒性休克和ICU入住率相近。
适用人群与场景
- 2010-2017年德州≥18岁脓毒症住院患者,包括合并与不合并MS者;敏感性分析纳入脓毒性休克患者和入住ICU的脓毒症住院患者。
研究设计与关键结果
- 回顾性人群队列研究,基于德州全州数据集,纳入283,025例脓毒症住院,其中MS 1,687例(0.6%)。
- MS组与无MS组:年龄≥65岁35.0% vs 56.8%,少数族裔36.2% vs 48.1%,Deyo合并症指数均值1.6 vs 2.7;脓毒性休克58.7% vs 59.6%,ICU入住46.7% vs 46.0%。
- 未校正短期死亡率:全队列MS组20.2% vs 无MS组31.3%;脓毒性休克亚组25.6% vs 40.0%;ICU亚组24.0% vs 34.8%。
- 校正后MS与短期死亡率降低17%相关(aOR 0.828,95%CI 0.723-0.947)。
- 脓毒性休克亚组校正后MS与短期死亡率降低相关(aOR 0.764,95%CI 0.651-0.896);ICU亚组MS与死亡率无关(aOR 0.914,95%CI 0.759-1.101)。
证据类型、等级与局限
- 证据类型:回顾性人群队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:MS与脓毒症患者较低的短期死亡率相关,脓毒性休克亚组结果一致;在入住ICU的脓毒症患者中MS与死亡率无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Multiple sclerosis (MS) is associated with increased risk of sepsis and higher sepsis-related mortality, compared to the general population. However, the evidence on the prognostic impact of MS in sepsis has been scarce. We aimed to evaluate the population-level association of MS with short-term mortality in sepsis.
METHODS: We performed a retrospective population-based cohort study using a statewide data set to identify hospitalizations aged ≥ 18 years in Texas with sepsis, with and without MS during 2010-2017. Multilevel logistic models were fit to estimate the association of MS with short-term mortality among all sepsis hospitalizations, and for sensitivity analyses among hospitalizations with septic shock and those admitted to ICU.
RESULTS: Among 283,025 sepsis hospitalizations, 1687 (0.6%) had MS. Compared to sepsis hospitalizations without MS, those with MS were younger (aged ≥ 65 years 35.0% vs 56.8%), less commonly racial/ethnic minority (36.2% vs 48.1%), and had lower mean Deyo comorbidity index (1.6 vs 2.7). The rates of septic shock and ICU admission were similar for sepsis hospitalizations with and without MS (58.7% vs 59.6% and 46.7% vs 46.0%, respectively). The unadjusted short-term mortality among sepsis hospitalizations with and without MS for the whole cohort, among those with septic shock, and among ICU admissions were 20.2% vs 31.3%, 25.6% vs 40.0%, and 24.0% vs 34.8%, respectively. On adjusted analyses, MS was associated with 17% lower odds of short-term mortality (adjusted odds ratio [aOR] 0.828 [95% CI 0.723-0.947]). Similar findings were observed on sensitivity analyses of patients with septic shock (aOR 0.764 [95% CI 0.651-0.896]), but MS was not associated with mortality among sepsis hospitalizations admitted to ICU (aOR 0.914 [95% CI 0.759-1.101]).
CONCLUSIONS: MS was associated with lower short-term mortality among septic patients, with findings consistent among the subset with septic shock. Among septic patients admitted to ICU, MS was not associated with mortality.
参考来源
- Oud L, Garza J. Association of multiple sclerosis with mortality in sepsis: a population-level analysis. J Intensive Care. 2022. PMID: 35879778. doi:10.1186/s40560-022-00628-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。